secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001437749-24-033055
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics Q3 BRIUMVI revenue $83.3M, raises FY2024 guidance to $300-$305M
-------------------------------------------------------------------------------

- BRIUMVI Q3 U.S. net sales $83.3M, up 15% QoQ and 230% YoY; full-year target raised to $300-$305M.
- Net income $3.9M in Q3 vs $113.9M a year ago (prior period included $140M upfront payment); cash $341M.
- Phase 1 trial of subcutaneous ublituximab initiated; FDA cleared IND for azer-cel in progressive MS.
- Secured FUJIFILM Diosynth as secondary U.S. manufacturer of BRIUMVI.
- Five-year ECTRIMS data: 92% of patients free from disability progression; annualized relapse rate 0.02.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000143774924033055/0001437749-24-033055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000143774924033055/tgtx20241103_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-033055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer